Market Exclusive

ABBVIE INC. (NYSE:ABBV) Files An 8-K Submission of Matters to a Vote of Security Holders

ABBVIE INC. (NYSE:ABBV) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07.Submission of Matters to a Vote of Security Holders.

AbbVie Inc. (AbbVie) held its Annual Meeting of Stockholders on
May5, 2017. The following is a summary of the matters voted on at
that meeting.

(1) The stockholders elected AbbVies ClassII Directors with terms
expiring in 2020, as follows:

Name

For

Against

BrokerNon-Votes

Robert J. Alpern

1,118,328,511

10,737,541

280,277,501

Edward M. Liddy

1,113,185,998

15,880,054

280,277,501

Melody B. Meyer

1,121,539,612

7,526,440

280,277,501

Frederick H. Waddell

1,119,615,307

9,450,745

280,277,501

(2) The stockholders ratified the appointment of Ernst Young LLP
as AbbVies independent registered public accounting firm for
2017, as follows:

For

Against

Abstain

1,392,413,822

14,065,091

2,864,640

(3) The stockholders approved, on an advisory basis, the
compensation of AbbVies named executive officers listed in the
proxy statement for the 2017 annual meeting, as follows:

For

Against

Abstain

BrokerNon-Votes

1,066,989,000

50,885,097

11,191,955

280,277,501

(4) The stockholders did not approve the management proposal
regarding amendment of the certificate of incorporation for the
annual election of directors, as follows:

For

Against

Abstain

BrokerNon-Votes

1,116,988,345

7,082,900

4,994,807

280,277,501

(5) The stockholders did not approve a stockholder proposal to
issue a lobbying report, as follows:

For

Against

Abstain

BrokerNon-Votes

280,902,158

774,007,636

74,156,258

280,277,501

(6) The stockholders did not approve a stockholder proposal to
separate chair and CEO, as follows:

For

Against

Abstain

BrokerNon-Votes

386,900,232

735,332,171

6,833,649

280,277,501

About ABBVIE INC. (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products. ABBVIE INC. (NYSE:ABBV) Recent Trading Information
ABBVIE INC. (NYSE:ABBV) closed its last trading session down -0.04 at 66.17 with 4,497,397 shares trading hands.

Exit mobile version